Vox Markets talks to Jeremy Skillington, chief executive of infectious disease specialist Poolbeg Pharma, about a year which has seen its drug development programmes moving forward at pace thanks to its unique capital-light and AI led approach to R&D.
00:00 Intro
00:47 Stated milestones hit throughout a year of major newsflow for the company, and strengthening the team to advance business development and clinical studies
02:51 Describing the unique “capital light” business model and its advantages
04:07 The use of artificial intelligence in the drug discovery process, deals signed with AI partners, and upcoming milestones for AI analysis
09:06 Progress of POLB 001, including the completion of its human challenge study without serious adverse events and aims to be partner-ready in 2023
12:02 What’s next on the road to POLB 001 commercialisation
13:43 The advantages of orally delivered vaccines, Poolbeg’s collaboration with encapsulation specialist AnaBio on obesity and diabetes treatments, and plans for an exploratory trial in 2023
16:24 Progress on other drugs in the pipeline, POLB 002 and POLB 003
18:09 Balance sheet strength supporting programmes through to commercialisation
19:01 Seeking out further potential drug candidates
#POLB #Stockstofollow #smallcaps #smallcapsinvesting #VoxMarkets #FinancialNews #CompanyNews #trading #investing #stocks #shares #money
